Monoclonal antibody · Antagonist of CD39 (ectonucleoside triphosphate diphosphohydrolase-1) (ENTPD1) · developed by Innate Pharma
IPH5201 is a monoclonal antibody that binds the cell surface ectonucleosidase CD39, blocking its conversion of extracellular ATP to AMP and thereby raising ATP and lowering immunosuppressive adenosine in the tumor microenvironment. It is being studied in non-small cell lung cancer, in combination with durvalumab and standard chemotherapy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05742607 | Phase 2 | Non Small Cell Lung Cancer | Recruiting | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non Small Cell Lung Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →